Company profile

Randall A. Lipps
Incorporated in
Fiscal year end
Industry (SEC)
Former names
Omnicell Com, Omnicell Inc
IRS number

OMCL stock data

FINRA relative short interest over last month (20 trading days) ?


1 Nov 19
21 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 228.81M 217.41M 202.52M 211.75M
Net income 19.98M 15.98M 3.28M 14.79M
Diluted EPS 0.46 0.37 0.08 0.36
Net profit margin 8.73% 7.35% 1.62% 6.99%
Operating income 24.65M 18.76M 12.76M 18.93M
Net change in cash 49.8M 10.24M 10.05M 23.02M
Cash on hand 137.28M 87.48M 77.24M 67.19M
Cost of revenue 116.66M 113.37M 105.4M 109.57M
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 787.31M 712.71M 695.91M 484.56M
Net income 37.73M 30.52M 9.76M 30.76M
Diluted EPS 0.93 0.79 0.26 0.84
Net profit margin 4.79% 4.28% 1.40% 6.35%
Operating income 44.39M 11.15M 21.41M 48.63M
Net change in cash 34.77M -22.06M -27.73M -43.67M
Cash on hand 67.19M 32.42M 54.49M 82.22M
Cost of revenue 414.98M 394.08M 378.82M 236.63M

Financial data from Omnicell earnings reports

98.1% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 285 276 +3.3%
Opened positions 41 33 +24.2%
Closed positions 32 46 -30.4%
Increased positions 100 108 -7.4%
Reduced positions 102 92 +10.9%
13F shares
Current Prev Q Change
Total value 4.85B 3B +61.7%
Total shares 41.15M 41.48M -0.8%
Total puts 15.49K 15.51K -0.1%
Total calls 91.3K 91.35K -0.1%
Total put/call ratio 0.2 0.2 -0.1%
Largest owners
Shares Value Change
BLK BlackRock 6.77M $553.23M +4.3%
Vanguard 4.48M $365.75M +1.4%
Wellington Management 3.76M $307.57M +1.9%
Conestoga Capital Advisors 1.58M $128.93M -0.2%
CS Credit Suisse 1.47M $120.14M +7.3%
STT State Street 1.21M $98.62M +2.4%
Dimensional Fund Advisors 973.46K $79.55M -2.8%
Eagle Asset Management 838.47K $68.52M -0.4%
N Price T Rowe Associates 730.08K $59.66M +2.6%
JHG Janus Henderson 690.34K $56.41M -1.5%
Largest transactions
Shares Bought/sold Change
BLK BlackRock 6.77M +282.01K +4.3%
Voya Investment Management 182.44K -202.84K -52.6%
Braun Stacey Associates 21.16K -183.95K -89.7%
Castleark Management 0 -159.44K EXIT
SG Capital Management 0 -152.19K EXIT
IVZ Invesco 595.15K -148.42K -20.0%
Marshall Wace 142.79K +135.63K +1894.2%
CS Credit Suisse 1.47M +99.58K +7.3%
Fisher Asset Management 317.04K -99.31K -23.9%
Redwood Investments 260.22K -97.2K -27.2%

Financial report summary

  • If we fail to develop new products or enhance our existing products to react to rapid technological change and market demands in a timely and cost-effective manner, or if newly developed solutions, such as our XT Series, XR2 Automated Central Pharmacy System, and IVX Workflow, are not adopted in the same time frame and/or quantity as we anticipate, our business will suffer.
  • We operate in highly competitive markets, and we may be unable to compete successfully against new entrants and established companies with greater resources and/or existing business relationships with our current and potential customers.*
  • Unfavorable economic and market conditions, a decreased demand in the capital equipment market, and uncertainty regarding the rollout of government legislation in the healthcare industry could adversely affect our operating results.
  • The transition to selling more products which include a software as a service or solution as a service subscription presents a number of risks.
  • We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position.*
  • We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business.*
  • If we experience a significant disruption in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions, our business could be adversely affected.
  • We may fail to realize the potential benefits of recently acquired businesses.
  • If goodwill or other intangible assets that we recorded in connection with the Aesynt, Ateb, and InPharmics acquisitions, or have recorded in connection with prior acquisitions, become impaired, we could be required to take significant charges against earnings.
  • We may not be able to successfully integrate acquired businesses or technologies into our existing business, which could negatively impact our operating results.
  • Changing customer requirements could decrease the demand for our products and services, and our new product solutions may not achieve market acceptance.
  • The healthcare industry faces changes to healthcare legislation and other healthcare reform, as well as financial constraints and consolidation, which could adversely affect the demand for our products and services.
  • Government regulation of the healthcare industry could reduce demand for our products, or substantially increase the cost to produce our products.
  • When we experience delays in installations of our medication and supply dispensing systems or our more complex medication packaging systems, resulting in delays in our ability to recognize revenue, our competitive position, results of operations, and financial condition could be harmed.
  • Our international operations may subject us to additional risks that can adversely affect our operating results.*
  • In the past, we have experienced substantial fluctuations in customer demand, and we cannot be sure that we will be able to respond proactively to future changes in customer demand.
  • Covenants in our Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and results of operations could be adversely affected.
  • If we are unable to recruit and retain skilled and motivated personnel, our competitive position, results of operations, and financial condition could be harmed.
  • Our failure to protect our intellectual property rights could negatively affect our ability to compete.
  • Our quarterly operating results may fluctuate and may cause our stock price to decline.*
  • If we are unable to maintain our relationships with group purchasing organizations or other similar organizations, we may have difficulty selling our products and services to customers represented by these organizations.
  • If we are not able to supply the demand from our institutional and retail pharmacy customers on schedule and with quality consumable medication packaging products, or if we are otherwise unable to maintain our relationships with major institutional pharmacies, they may use alternative means to distribute medications to their customers and our revenue from sales of blister cards and other consumables may decline.*
  • If we are unable to successfully interface our automation solutions with the existing information systems of our customers, they may choose not to use our products and services.
  • We depend on a limited number of suppliers for our products, and our business may suffer if we were required to change suppliers to obtain an adequate supply of components, equipment, and raw materials on a timely basis.
  • Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline.
  • If the market price of our common stock continues to be highly volatile, the investment value of our common stock may decline.*
  • Our U.S. government lease agreements are subject to annual budget funding cycles and mandated unilateral changes, which may affect our ability to enter into such leases or to recognize revenues, and sell receivables based on these leases.
  • If we fail to manage our inventory properly, our revenue, gross margin, and profitability could suffer.
  • Intellectual property claims against us could harm our competitive position, results of operations, and financial condition.
  • Our software products are complex and may contain defects, which could harm our reputation, results of operations, and financial condition.
  • Product liability claims against us could harm our competitive position, results of operations and financial condition.
  • We are dependent on technologies provided by third-party vendors, the loss of which could negatively and materially affect our ability to market, sell, or distribute our products.
  • Complications in connection with our ongoing business information system upgrades, including those required to transition acquired entities onto information systems already utilized, and those implemented to adopt new accounting standards, may impact our results of operations, financial condition, and cash flows.
  • Outstanding employee stock options have the potential to dilute stockholder value and cause our stock price to decline.
  • Raising additional capital may cause dilution to our existing stockholders, restrict our operations or harm our business, financial condition, and results of operations.
  • Changes in our tax rates, exposure to additional tax liabilities, or the adoption of new tax legislation could adversely affect our business and financial condition.
  • Catastrophic events may disrupt our business and harm our operating results.
  • The conflict minerals provisions of the Dodd-Frank Wall Street Reform and Consumer Protection Act could result in additional costs and liabilities.
  • Anti-takeover provisions in our charter documents and under Delaware law, and any stockholders' rights plan we may adopt in the future, make an acquisition of us, which may be beneficial to our stockholders, more difficult.
Management Discussion
  • Product revenues represented 74% and 73% of total revenues for the three months ended September 30, 2019 and 2018, respectively. Product revenues increased by $18.8 million, primarily due to an increase in our Automated Dispensing Cabinet business, driven primarily by the growth of XT series products, partially offset by a decrease in sales of Performance Center, primarily due to a large installation during the three months ended September 30, 2018.
  • Services and other revenues represented 26% and 27% of total revenues for the three months ended September 30, 2019 and 2018, respectively. Services and other revenues include revenues from service and maintenance contracts, and rentals of automation systems. Services and other revenues increased by $5.8 million, primarily due to higher service renewal fees, driven mainly by an increase in our installed customer base, as well as an increase in revenues from Population Health Solutions.
  • Our international sales represented 10% and 12% of total revenues for the three months ended September 30, 2019 and 2018, respectively, and are expected to be affected by foreign currency exchange rate fluctuations. We are unable to predict the extent to which revenues in future periods will be impacted by changes in foreign currency exchange rates.
Content analysis ?
H.S. sophomore Avg
New words: Albemarle, appointed, Denver, disappear, Frank, Interbank, lift, London, moot, pleading, refiling, requesting, vii, voluntarily
Removed: Infor, MedKeeper, Talyst